These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27189470)

  • 1. Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer's Disease Patients?
    Femminella GD; Leosco D; Ferrara N; Rengo G
    CNS Neurol Disord Drug Targets; 2016; 15(6):665-71. PubMed ID: 27189470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
    Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer's Disease.
    Fitzgerald PJ
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
    Cheng YJ; Lin CH; Lane HY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impairments: Lessons from preclinical studies.
    Talebi M; İlgün S; Ebrahimi V; Talebi M; Farkhondeh T; Ebrahimi H; Samarghandian S
    Biomed Pharmacother; 2021 Jan; 133():111088. PubMed ID: 33378982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer's disease.
    Liang HY; Zhang PP; Zhang XL; Zheng YY; Huang YR; Zheng GQ; Lin Y
    Aging (Albany NY); 2021 Mar; 13(5):7549-7569. PubMed ID: 33686024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2014; 42(4):1079-149. PubMed ID: 25061058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The β-adrenergic hypothesis of synaptic and microglial impairment in Alzheimer's disease.
    Li S
    J Neurochem; 2023 May; 165(3):289-302. PubMed ID: 36799441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease.
    Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AD: are we intervening too late?
    Korczyn AD
    J Neural Transm (Vienna); 2011 Sep; 118(9):1359. PubMed ID: 21863300
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
    Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Matsunaga S; Kishi T; Annas P; Basun H; Hampel H; Iwata N
    J Alzheimers Dis; 2015; 48(2):403-10. PubMed ID: 26402004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Insulin for Alzheimer's Disease.
    Hallschmid M
    CNS Drugs; 2021 Jan; 35(1):21-37. PubMed ID: 33515428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
    Youdim MB; Buccafusco JJ
    J Neural Transm (Vienna); 2005 Apr; 112(4):519-37. PubMed ID: 15666041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease.
    Robbins TW; McAlonan G; Muir JL; Everitt BJ
    Behav Brain Res; 1997 Feb; 83(1-2):15-23. PubMed ID: 9062655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
    Li L; Xu S; Liu L; Feng R; Gong Y; Zhao X; Li J; Cai J; Feng N; Wang L; Wang X; Peng Y
    J Alzheimers Dis; 2017; 56(4):1403-1417. PubMed ID: 28157092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?
    Rampa A; Gobbi S; Belluti F; Bisi A
    Curr Top Med Chem; 2013; 13(15):1879-904. PubMed ID: 23931436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil improves the cognitive impairment in a tree shrew model of Alzheimer's disease induced by amyloid-β
    Zheng H; Niu S; Zhao H; Li S; Jiao J
    Metab Brain Dis; 2018 Dec; 33(6):1961-1974. PubMed ID: 30105614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.